Last updated: February 13, 2024
Sponsor: Boston Children's Hospital
Overall Status: Active - Recruiting
Phase
2
Condition
Pancreatitis
Treatment
Opioid
Ketorolac
Clinical Study ID
NCT04291599
P00034168
Ages < 21 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients who present to the ED and are admitted to BCH with a diagnosis of acutepancreatitis or an acute bout of chronic pancreatitis based on INSPPIRE14 Criteria (Appendix 1)
- Age ≤21 years
- Patient weight ≥8 kg
Exclusion
Exclusion Criteria:
- Allergy to morphine (and hydromorphone) or aspirin/NSAID
- History of renal or hepatic insufficiency
- History of peptic ulceration
- History of bleeding diathesis
- Pregnant females
- Patients who have a documented history of substance abuse disorder or those who useopioids chronically
- Patients admitted to the Intensive Care Unit (ICU)
- Patients who received intravenous opioid patient-controlled analgesia (PCA) in transitor during their ED admission.
Study Design
Total Participants: 50
Treatment Group(s): 2
Primary Treatment: Opioid
Phase: 2
Study Start date:
March 15, 2022
Estimated Completion Date:
June 30, 2024
Study Description
Connect with a study center
Boston Children's Hospital
Boston, Massachusetts 02115
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.